Q2 FY26: Revenue up 16% YoY, PAT jumps 36%

Pat Growth 25pctResults View source PDF Explain this filing

ALIVUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.0%Reaction day

₹890.00

prior close

₹925.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.4%+2.6% vs market

Pharmaceuticals peers, median of 156sector-0.1%+3.1% vs sector

On the reaction day the stock moved 2.6 pts more than Nifty Microcap 250 and 3.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.1

10m

-1.1

15m

-1.2

30m

-1.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.0+0.4+2.6-0.1+3.1

Next day

+3.7+0.0+3.7-0.7+4.4

+2.4-0.2+2.6-1.0+3.4

+2.3+0.7+1.6+0.1+2.2

+1.4+0.6+0.8+0.2+1.2

+2.2+0.5+1.7-0.0+2.2

+3.7+0.3+3.4-0.3+4.0

15d

+0.7-1.5+2.1-1.7+2.4

-3.8-6.6+2.7-5.4+1.5

+3.5-3.2+6.7-2.9+6.4

+5.6-5.2+10.8-7.4+13.0

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alivus Life Sciences (formerly Glenmark Life Sciences) reported Q2 FY26 revenue of Rs 587.98 crore, up 16% YoY. PAT rose 36% to Rs 130.03 crore from Rs 95.32 crore. H1 FY26 revenue grew 8.6% to Rs 1,189.83 crore; PAT up 21.6% to Rs 251.56 crore. PBT margins expanded. Auditor gave an unmodified review. Q2 EPS was Rs 10.60 vs Rs 7.78.

Likely market impact

Strong Q2 with double-digit revenue growth and 36% PAT jump, backed by expanding margins. Positive earnings momentum for shareholders.